Introduction
When characterising any inhalation product, a comprehensive assessment including in vitro, pharmacokinetic (PK), as well as clinical results is required. We therefore assessed tiotropium Respimat® when administered with the AeroChamber Plus® Flow-Vu® antistatic valved holding chamber (test VHC) using in vitro and PK data, as well as clinical results in 1-5-year-olds with persistent asthmatic symptoms.
Methods
We evaluated tiotropium delivered into a cascade impactor under fixed pediatric flow rates with and without holding times in the test VHC. Tidal breathing simulations and an ADAM-III Child Model were employed to assess the tiotropium mass likely to reach the lungs of preschool children when Respimat® was administered with the test VHC. Clinical characterisation was based on a 12-week, double-blind, randomised, parallel-group trial of once-daily tiotropium Respimat® or placebo as add-on to background therapy in 1-5-year-olds with persistent asthmatic symptoms (NCT01634113). PK data on systemic exposure to tiotropium Respimat® administered with test VHC in preschool children was compared with pooled data from nine trials in older patients with symptomatic persistent asthma not using VHCs (NCT01383499/NCT01122680/NCT01233284/NCT01152450/NCT01696071/NCT00772538/NCT 00776984/NCT01172808/NCT01172821).
Results
In vitro emitted mass decreased with lower flow conditions, indicating age-dependent dose reduction. In terms of dose per kg/body weight, delivered dosing at flow rates corresponding to preschool children was comparable to that at flow rates corresponding to older children (Table) . Transmission and holding properties of tiotropium Respimat® administered with the test VHC were fully sufficient for aerosol delivery of patients. Standardised tidal inhalation resulted in emitted mass from the test VHC of approximately one-third of labelled dose, independent of coordination and use of face mask, indicating predictable tiotropium administration by Respimat® when used with the test VHC. Data generated from the anatomically correct ADAM-III model correlated well with standardised tidal breathing results, both in terms of total mass delivered and the mass delivered to filter (available to the lungs). In separate clinical trials, tiotropium exposure in 1-5-year-old patients using the test VHC, adjusted by height or body surface, was comparable with that observed in older patients who did not use VHCs; no overexposure was observed. The safety profile of tiotropium Respimat® in 1-5-year-old patients was comparable to placebo. Conclusion This study supports administration of tiotropium Respimat® with the AeroChamber Plus® FlowVu® test VHC in 1-5-year-old children with persistent asthmatic symptoms.
